Statin use in patients with cirrhosis: A retrospective cohort study

Digestive Diseases and Sciences

Volumn 59, Issue 8, 2014, Pages 1958-1965

  Kumar, Sonal ^a,b   Grace, Norman D ^a   Qamar, Amir A ^a,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

Child Pugh; Cirrhosis; Decompensation; Statins

Indexed keywords

ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BILIRUBIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGE; ALBUMIN BLOOD LEVEL; ARTICLE; ASCITES; BILIRUBIN BLOOD LEVEL; CHILD PUGH SCORE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DECOMPENSATED LIVER CIRRHOSIS; DIABETES MELLITUS; DRUG USE; END STAGE LIVER DISEASE; ESOPHAGUS VARICES; FEMALE; GENDER; HEPATIC ENCEPHALOPATHY; HUMAN; HUMAN TISSUE; JAUNDICE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SCORING SYSTEM;

AGED; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KAPLAN-MEIER ESTIMATE; LIVER CIRRHOSIS; MALE; MASSACHUSETTS; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES;

EID: 84905580178     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-014-3179-2     Document Type: Article

References (39)

1. Targher G, Bertolini L, Padovani R, Rodella S, Acaro G, Day C. Differences and similarities in early atherosclerosis between patients with nonalcoholic steatohepatitis and chronic hepatitis B and C. J Hepatol. 2007;46:1126-1132. (Pubitemid 46669732)
2. Longo M, Crosignani A, Battezzati PM, et al. Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. Gut. 2002;51:265-269. (Pubitemid 34791459)
3. Loria P, Lonardo A, Bellentani S, et al. Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: an open question. Nutr Metab Cardiovasc Dis. 2007;17:684-698. (Pubitemid 47593074)
4. Kalaitzakis E, Rosengren A, Skommevik T, Bjornsson E. Coronary artery disease in patients with liver cirrhosis. Dig Dis Sci. 2010;55:467-475.
5. Tiukinhoy-Laing SD, Rossi JS, Bayram M, et al. Cardiac hemodynamic and coronary angiographic characteristics of patients being evaluated for liver transplantation. Am J Cardiol. 2006;98:178-181. (Pubitemid 43975507)
6. Raval Z, Harinstein ME, Skaro AI, et al. Cardiovascular risk assessment of the liver transplant candidate. J Am Coll Cardiol. 2011;58:223-231.
7. Palmer SC, Craig JC, Navaneethan SD, Tonelli M, Pellegrini F, Strippoli GF. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012;157:263-275.
8. Wiesbauer F, Heinze G, Mitterbauer C, Harnoncourt F, Horl WH, Oberbrauer R. Statin use is associated with prolonged survival of renal transplant recipients. J Am Soc Nephrol. 2008;19:2211-2218.
9. Frohlich GM, Rufiback K, Enseleit F, et al. Statins and the risk of cancer after heart transplantation. Circulation. 2012;126:440-447.
10. Douglas I, Evans S, Smeeth L. Effect of statin treatment on short term mortality after pneumonia episode: cohort study. BMJ. 2011;42:1642.
11. Poynter JN, Gruber SB, Higgins PDR, et al. Statins and the risk of colorectal cancer. N Engl J Med. 2005;352:2184-2192. (Pubitemid 40727085)
12. Boudreau DM, Gardner JS, Malone KE, Heckbert SR, Blough DK, Daling JR. The association between 3-hydroxy-3-methylglutaryl coenzyme A inhibitor use and breast carcinoma risk among postmenopausal women: a case-control study. Cancer. 2004;100:2308-2316. (Pubitemid 38657877)
13. Friis S, Poulsen AH, Johnsen SP, et al. Cancer risk among statin users: a population-based cohort study. Int J Cancer. 2005;114:643-647. (Pubitemid 40349625)
14. Marcella SW, David A, Ohman-Strickland PA, Carson J, Rhoads GG. Statin use and fatal prostate cancer: a matched case-control study. Cancer. 2012;118:4046-4052.
15. El-Serag HB, Johnson ML, Hachem C, Morgana RO. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology. 2009;136:1601-1608.
16. Tsan YT, Lee CH, Wang JD, Chen PC. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J Clin Oncol. 2012;30:623-630.
17. Russo MW, Jacobson IM. How to use statins in patients with chronic liver disease. Cleve Clin J Med. 2004;71:58-62. (Pubitemid 39220369)
18. Stancu C, Sima A. Statins: mechanism of action and effects. J Cell Mol Med. 2001;5:378-387.
19. Parra JL, Reddy KR. Hepatotoxicity of hypolipidemic drugs. Clin Liver Dis. 2003;7:415-433. (Pubitemid 36807740)
20. Calderon RM, Cubeddu LX, Goldberg RB, Schiff ER. Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma. Mayo Clin Proc. 2010;85:349-356.
21. Argo CK, Loria P, Caldwell SH, Lonardo A. Statins in liver disease: a molehill, an iceberg or neither? Hepatology. 2008;48:662-669.
22. Vuppalanchi R, Teal E, Chalasani N. Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal liver enzymes. Am J Med Sci. 2005;329:62-65. (Pubitemid 40250595)
23. Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology. 2005;41:690-695. (Pubitemid 40462927)
24. Onofrei MD, Butler KL, Fuke DC, Miller HB. Safety of statin therapy in patients with preexisting liver disease. Pharmacotherapy. 2008;28:522-529. (Pubitemid 351466463)
25. Khorashadi S, Hasson NK, Cheung RC. Incidence of statin hepatotoxicity in patients with hepatitis C. Clin Gastroenterol Hepatol. 2006;4:902-907. (Pubitemid 43994535)
26. Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology. 2004;126:1287-1292. (Pubitemid 38552793)
27. Lewis JH, Mortensen ME, Zweig S, et al. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology. 2007;46:1453-1463. (Pubitemid 350155527)
28. Avins AL, Manos MM, Zhao W. Hepatic effects of lovastatin exposure in patients with liver disease. Drug Saf. 2008;31:325-334. (Pubitemid 351441580)
29. Cohen DE, Anania FA, Chalasani N, National lipid association statin safety task force liver expert panel. An assessment of statin safety by hepatologists. Am J Cardiol. 2006;97:77C-81C.
30. Lewis JH. Clinical perspective: statins and the liver - harmful or helpful? Dig Dis Sci. 2012;57:1754-1763.
31. Trebicka J, Hennenberg M, Laleman W, et al. Atorvastatin lowers portal pressures in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology. 2007;46:242-253. (Pubitemid 47171941)
32. Zafra C, Albrades JG, Turnes J, et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology. 2004;126:749-755. (Pubitemid 38298323)
33. Albrades JG, Lapillus A, Banares R, et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology. 2009;136:1651-1658.
34. Morena M, Ramalho LN, Sancho-Bru P, et al. Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver. Am J Physiol Gastrointest Liver Physiol. 2009;296:G147-G156.
35. Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L et al. Efficacy of cholesterol lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371:117-125.
36. Tonelli M, Lloyd A, Clement F, et al. Efficacy of statins for primary prevention in people at low cardiovascular risk: a metaanalysis. CMAJ. 2011;183:E1189-E1202.
37. Tsochatzis EA, Bosch J, Burroughs AK. Prolonging survival in patients with cirrhosis: old drugs with new indications. Gastroenterology. 2010;139:1813-1815.
38. PDR Staff. Physicians' desk reference. PDR Network; 2011.
39. Berzigotti A, Garcia-Tsao G, Bosch J, et al. Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. Hepatology. 2011;54:555-561.